Skip to main content

Updated from 12:13 p.m. EDT

It seems that



cannot get away from the big deal that got away.

The Wilmington, N.C.-based drug company has been sued by

Cima Labs


, which is seeking to recover the $11.5 million break-up fee it paid to aaiPharma after Cima called off their merger last year.

Cima also wants at least $5 million in damages, arguing that aaiPharma misled Cima and investors about its financial health.

Cima eventually agreed to be acquired by

TheStreet Recommends



of West Chester, Pa., in a deal that was finally approved by the Federal Trade Commission on Monday. The transaction, in which Cima shareholders received $34 a share, closed late Thursday afternoon, making Cima a wholly-owned subsidiary of Cephalon.

Cima's lawsuit was announced Wednesday, a few days after aaiPharma revealed that a Cima representative had inquired about getting a refund on the breakup fee. In its latest 10-Q filing, aaiPharma said it would keep the money and fight any lawsuit.

Cima, based in Eden Prairie, Minn., filed suit in Hennepin County District Court, accusing aaiPharma of fraud and breach of contract relating to the merger agreement they signed 12 months ago. After Cima accepted Cephalon's offer in November, Cima paid the break-up fee to aaiPharma.

Cima bases its complaint on revelations by aaiPharma that have provoked investigations from the

Securities and Exchange Commission

and the Justice Department about aaiPharma's product-selling and accounting practices. The company recently restated earnings reports for 2002 and 2003.

Cima's lawsuit alleges that it never would have considered a merger if it had known about aaiPharma's true financial condition. In addition to the $11.5 million break-up fee, Cima said it wants more than $5 million in expenses and fees related to its evaluation and negotiation of aaiPharma's offer.

"Had aaiPharma's financial results as restated been public, we would not have entered into a merger agreement with the company," Steven B. Ratoff, Cima's chairman, said Wednesday. "Under the circumstances, we believe it is appropriate to seek recovery of the break-up fee and recoup the significant fees and expenses we incurred in connection with negotiating the transaction."

Although Cima announced the filing of the suit about an hour after markets had closed on Wednesday, there was a furious flurry of selling in aaiPharma's stock in the final minutes of the regular trading session. Shares of aaiPharma plunged 15.8%, of 49 cents, to reach $2.62. Most of the decline came within the final 30 minutes of regular trading. Normal daily trading volume is about 523,000 shares, Nearly 912,000 shares were traded Wednesday, mostly in the last few minutes.

In trading Thursday, aaiPharma's stock was down 12 cents, or 4.6%, to $2.50.